

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Tetsuo TSUJI et al. Conf.:  
Appl. No.: NEW Group: Unassigned  
Filed: October 31, 2003 Examiner: Unassigned  
For: MONOCLONAL ANTIBODY RECOGNIZING C-TERMINUS OF hBNP

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION WITH CONTINUATION-IN-PART OR  
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

October 31, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicants hereby submit an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form, attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form is requested since any patents, publications, or other information which are listed on the PTO-1449 form but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. Nos.  
09/942,709  
08/749,031  
08/236,013  
07/976,457

U.S. Filing Dates  
August 31, 2001  
November 14, 1996  
May 2, 1994  
November 13, 1992

III. FEES


This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #32,868  
Gerald M. Murphy, Jr., #28,977

  
GMM/KJR/bsh

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment(s) : ☒ PTO-1449(s)  
☐ References  
☐ Foreign Search Report  
☐ Other:

(Rev. 09/30/03)

Form PTO-1449				ATTY. DOCKET NO. 0032-0284P		APPLICATION NO. NEW	
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)				APPLICANT Tetsuo TSUJI et al.			
				FILING DATE October 31, 2003		GROUP Unassigned	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US 5,786,163		1998-07	Hall			
	US 6,376,207	B1	2002-04	Mischak et al.			
	US 6,162,902		2000-12	Mischak et al.			
	US 6,124,430		2000-09	Mischak et al.			
	US						
<b>FOREIGN PATENT DOCUMENTS</b>							
Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
	EP	A2	1989-08-03	EPO			YES    NO
<b>OTHER DOCUMENTS</b> (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)							
	S. Hashida et al., Clinica Chimica Acta, 175 (1988) 11-18; "Enzyme immunoassay for alpha-human atrial natriuretic polypeptide - direct measurement of plasma level"						
	Bulinski, International Review of Cytology, Vol. 103, pp. 281-302 (1986), "Peptide Antibodies: New Tools for Cell Biology"						
	Takeyama et al., J.Imm.Math, Vol.130 (1990), pp. 217-222						
	Sutcliffe et al; Science, Vol. 219 (1983), pp. 660-666						
	Itoh et al., Endocrinology, Vol. 127, pp.1292-1300 (1990)						
	Takeyama et al., J. Imm. Meth., Vol. 130, pp.217-222 (1990)						
	Sutcliffe et al., Science, Vol. 219, pp.660-666 (1983)						
	Harlow et al., Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory, pp.578-582 (1988)						
	Mukoyama et al., The Lancet, Vol. 335, pp.801-802 (1990)						
	Mukoyama et al., J. Clin. Invest., Vol. 87, pp.1402-1412 (1991)						
	Patent Abstracts of Japan, Vol. 16, No. 140, p. 22, C 962, No. 3-297-392 (1992)						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							